The 4th Military Revolution is Happening

. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>

Michael Raab Biography and Net Worth

CEO of Ardelyx

President & Chief Executive OfficerMike has served as Ardelyx’s President and Chief Executive Officer since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA), one of the world’s largest and most successful venture capital firms, where he specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors.

Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. In this position, Mike launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of hyperphosphatemia, with over $1.0 billion in worldwide sales in 2013. Mike was also instrumental in the worldwide launch of Genzyme’s therapies for Gaucher disease, Ceredase and Cerezyme. Mike also spent two years with Genzyme’s diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers.

What is Michael Raab's net worth?: The estimated net worth of Michael Raab is at least $3.34 million as of May 23rd, 2023. Mr. Raab owns 887,655 shares of Ardelyx stock worth more than $3,337,583 as of June 7th. This net worth approximation does not reflect any other investments that Mr. Raab may own. Learn More about Michael Raab's net worth.
What is Michael Raab's salary?: As the CEO of Ardelyx, Inc., Mr. Raab earned a total compensation package of $4,230,994.00 in 2021. Mr. Raab earned a salary of $650,000.00, a bonus of $195,000.00, stock awards of $1,105,898.00, options awards of $2,085,096.00, non-equity compensation of $195,000.00, and no other miscellaneous compensation. Learn More on Michael Raab's salary.
How do I contact Michael Raab?: The corporate mailing address for Mr. Raab and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Michael Raab's contact information.
Has Michael Raab been buying or selling shares of Ardelyx?: During the last quarter, Michael Raab has sold $41,453.05 in Ardelyx stock. Most recently, Michael Raab sold 11,357 shares of the business's stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $3.65, for a transaction totalling $41,453.05. Following the completion of the sale, the chief executive officer now directly owns 887,655 shares of the company's stock, valued at $3,239,940.75. Learn More on Michael Raab's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 176,445 shares worth more than $316,906.76. The most recent insider tranaction occured on May, 23rd when insider Robert Ora Felsch sold 1,046 shares worth more than $3,817.90. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 5/23/2023.

Michael Raab Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/23/2023	Sell	11,357	$3.65	$41,453.05	887,655
2/21/2023	Sell	13,449	$3.00	$40,347.00	896,012
8/22/2022	Sell	6,146	$0.98	$6,023.08	662,680
6/6/2022	Sell	103,624	$0.65	$67,355.60	668,826
5/20/2022	Sell	6,124	$0.67	$4,103.08	772,450
2/22/2022	Sell	6,229	$0.67	$4,173.43
11/22/2021	Sell	2,607	$0.99	$2,580.93
8/20/2021	Sell	2,573	$1.32	$3,396.36	329,730
5/20/2021	Sell	2,534	$7.09	$17,966.06	214,754
9/15/2020	Sell	106,337	$5.61	$596,550.57
7/2/2020	Sell	23,128	$7.01	$162,127.28
6/1/2020	Sell	23,128	$7.33	$169,528.24	208,057
5/4/2020	Sell	15,941	$7.01	$111,746.41	208,057
4/17/2020	Sell	9,428	$7.02	$66,184.56	208,057
4/15/2020	Sell	500	$7.03	$3,515.00	208,057
3/2/2020	Sell	11,123	$7.00	$77,861.00
2/5/2020	Sell	25,000	$7.32	$183,000.00
6/4/2019	Sell	10,054	$2.54	$25,537.16
1/2/2019	Sell	19,644	$1.70	$33,394.80
9/8/2015	Sell	9,785	$20.29	$198,537.65	1,518

Michael Raab Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.

Today's Range

Now: $3.76

$3.66

$3.80

50 Day Range

MA: $4.25

$3.23

$4.95

2 Week Range

Now: $3.76

$0.49

$5.13

Volume

3,280,750 shs

Average Volume

6,633,801 shs

Market Capitalization

$806.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

WARNING TO ALL U.S. INVESTORS

From Behind the Markets | Ad

May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>

Here are 3 steps to prepare yourself

Michael Raab Biography and Net Worth

What is Michael Raab's net worth?

What is Michael Raab's salary?

How do I contact Michael Raab?

Has Michael Raab been buying or selling shares of Ardelyx?

Who are Ardelyx's active insiders?

Are insiders buying or selling shares of Ardelyx?